# Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

> **NCT06628713** · — · APPROVED_FOR_MARKETING · sponsor: **KalVista Pharmaceuticals, Ltd.**

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** Sebetralstat

## Key facts

- **NCT ID:** NCT06628713
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06628713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06628713, "Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06628713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*